There is a particular quality to October light on the Côte d'Azur — softer than the blinding white of August, slanted enough to catch the grain of the limestone hills above Nice, warm enough to keep the terraces open well into the evening. It is the month when the city belongs, briefly, to itself again: the summer crowds have retreated, the mimosa is still weeks away, and the Promenade des Anglais recovers something of its original, unhurried dignity. Into this interlude, on 6 October 2026, a gathering of a different kind arrives — one that places Nice not merely as a backdrop for leisure, but as a stage for serious scientific exchange.
The event is the IA dans le nouveau monde de la Pathologie Thoracique — an international congress of excellence dedicated to the integration of artificial intelligence into thoracic pathology. It takes place at the Hôtel Le Saint-Paul, on the boulevard Franck Pilatte, and is organised under the auspices of IHU RespirERA, the French national institute whose work sits at the intersection of respiratory medicine, data science, and clinical innovation.
A Discipline at an Inflection Point
Thoracic pathology — the diagnosis and management of diseases affecting the lungs, pleura, and mediastinum — has long been shaped by the limits of human perception: the radiologist's trained eye, the pathologist's slide, the pulmonologist's auscultation. Artificial intelligence is now pressing against those limits in ways that are neither simple nor without controversy. Machine-learning models can flag patterns in CT imaging that escape the human gaze; algorithms trained on thousands of biopsy slides can propose differential diagnoses in seconds. Whether these tools augment clinical judgment or risk displacing it is precisely the kind of question a congress of this calibre is designed to address.
The framing — le nouveau monde, the new world — is deliberate. It signals not a marginal technical update but a structural shift in how thoracic disease is seen, classified, and treated. The congress positions itself as a space for that reckoning: rigorous, international, and, one infers from the venue and the institutional backing, unafraid of disagreement.
'Excellence' in the congress's own description carries weight here — it is a word the French medical establishment does not deploy lightly.
The Setting as Argument
The choice of Nice is not incidental. The city has been quietly building a reputation as a hub for health innovation, anchored in part by the presence of IHU RespirERA and the broader ecosystem of the Université Côte d'Azur. The Hôtel Le Saint-Paul, on the eastern arc of the bay near the port, offers the kind of setting that encourages the long conversations that happen after the formal sessions end — a terrace with a view of the water, the particular ease that comes from being somewhere beautiful.
For delegates travelling from outside France, Nice is straightforward to reach: the airport sits almost within the city limits, with direct connections from most European capitals and beyond. The old town — its baroque churches, its covered market on the cours Saleya, its distinct Niçois identity that sits somewhere between Provençal and Italian — is a short walk from the conference address.
What awaits attendees, beyond the scientific programme itself, is a city in one of its finest seasonal moods. The sea remains swimmable into October. The restaurants are less pressured than in summer, the menus more considered. The hills above the city — the arrière-pays, with its perched villages and its light — are at their most inviting for those with a free afternoon.
For clinicians, researchers, and technologists working at the frontier of respiratory medicine, the congress on boulevard Franck Pilatte offers something increasingly rare: a dedicated, high-level forum in which the implications of AI for their discipline can be examined without haste, in a city that rewards the decision to show up in person.